Ionis Pharmaceuticals draws attention after a rare-disease therapy license agreement, keeping its RNA-targeted medicine ...
Discusses FDA Approval of TRYNGOLZA for Severe Hypertriglyceridemia and Acute Pancreatitis Risk Reduction June 24, ...
TripleLift, the Creative SSP powered by TL Spark, today announced new campaign results with StackAdapt on behalf of GUESS FRAGRANCES, showing how premium native video, custom audience strategy, and ...
TEKLYNX International, known for helping supply chains work with their RFID and barcode labeling software solutions, today announced being selected as the AIDC Company of the Year by SupplyTech ...
The U.S. FDA has approved olezarsen (Tryngolza) as the first treatment specifically shown to reduce both triglyceride levels ...
After 35 years engaged in the research and development of pharmaceutical products, Ionis began marketing its drugs for the ...
The approval of Ionis Pharmaceuticals’ Tryngolza for severe hypertriglyceridemia could spur “substantial growth” for the ...
The U.S. Food and Drug Administration (FDA) approved on Wednesday Ionis Pharmaceuticals, Inc.’s IONS Tryngolza (olezarsen) to ...
Bank of America has unveiled its top 10 U.S. ideas for the third quarter of 2026, highlighting companies the firm believes are well positioned across a range of sectors, with Ford Motor (F) emerging ...
Zacks Investment Research on MSN
IONS out-licenses ex-US rights for rare neurology drug to Recordati
Ionis Pharmaceuticals IONS signed a license agreement with Italy-based Recordati. Per the terms, Recordati will acquire ...
June 29 (Reuters) - Bitcoin miner and AI infrastructure firm Ionic Digital filed on Monday to go public through a direct ...
In May 2024, auroras were observed at unusually low latitudes across the globe, lighting up skies that rarely see such ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results